Bronchial arterial chemoembolization combined with tislelizumab for the treatment of locally advanced non-small cell lung cancer:analysis of its clinical effect
10.3969/j.issn.1008-794X.2025.05.006
- VernacularTitle:支气管动脉化疗栓塞联合替雷利珠单抗治疗局部晚期非小细胞肺癌临床效果分析
- Author:
Rong LIU
1
;
Houfa NING
;
Xinjiang CUI
Author Information
1. 261031 山东潍坊山 东第二医科大学附属医院介入血管外科中心
- Keywords:
bronchial arterial chemoembolization;
non-small cell lung cancer;
programmed cell death protein-1 receptor inhibitor;
interventional therapy
- From:
Journal of Interventional Radiology
2025;34(5):477-481
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the clinical efficacy of bronchial arterial chemoembolization(BACE)combined with tislelizumab in treating unresectable locally advanced non-small cell lung cancer(NSCLC)with negative driver gene.Methods The clinical data of 54 patients of locally advanced NSCLC with negative driver gene,who were admitted to the Affiliated Hospital of Shandong Second Medical University of China from April 2020 to April 2021,were retrospectively analyzed.Of the 54 patients,27 received BACE combined with Tislelizumab(combination group)and 27 received BACE alone(control group).After three cycles of BACE treatment,the patients were followed up for 20 months.The clinical short-term efficacy,the preoperative and postoperative karnofsky performance status(KPS)score,surgical complications and adverse event(AE)in both groups were statistically analyzed.The number of patients who obtained successful transformation after treatment and the median progression-free survival(mPFS)in both groups were calculated.Results The objective response rate(ORR)and disease control rate(DCR)of the combination group were higher than those of the control group(ORR:81.48％vs 55.56％and DCR:96.29％vs 77.78％).A total of 4 patients in the combination group met the requirements of R0 resection,and the transformation success rate was 14.81％,while no patient in the control group met the requirements of R0 resection,the difference between the two groups was statistically significant(P＜0.05).The mPFS of the combination group was 13.3 months,which was strikingly longer than 9.2 months of the control group(P＜0.05).The postoperative improvement rate of KPS score in the combination group was remarkably higher than that in the control group(77.78％vs 48.15％,P＜0.05).Conclusion For unresectable locally advanced NSCLC with negative driver gene,BACE combined with Tislelizumab can effectively kill tumor cells,thus the original unresectable tumor may be,in some extent,surgically treated with R0 resection,and a higher ORR as well as a higher DCR can be well expected,the patient's quality of life can be improved,and the patient's mPFS can be prolonged.
